Skip to content
GLP-1 Savers

Head-to-head · Value Score

CoreAge Rx vs Pallas Health

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 81, Pallas Health a 74. Compare their advertised prices, billing terms, and what to check before paying.

By Grant Ashford, Founder & Pricing Editor
★ Better value

CoreAge Rx

Grade B · Good Value

Advertised price

From $79/mo

From $79/mo (compounded semaglutide; confirm total at checkout)

Get this deal Full CoreAge Rx review →
VS

Pallas Health

Grade C+ · Watch List

Advertised price

$199/mo

$199/mo (Pallas's own average for $597 billed every 12 weeks — its only cadence)

Get this deal Full Pallas Health review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 81 to 74 — at an advertised price of From $79/mo (compounded semaglutide; confirm total at checkout). Check the pricing terms before enrolling. Pallas Health isn't out of it: Readers who want unusually specific disclosure about who prescribes and who dispenses, want the option of brand-name Zepbound or Wegovy from the same desk, and can absorb a $597 charge four weeks after the $139 one.

CoreAge Rx is a featured partner of this site. Its advertised prices have checkout conditions, and state eligibility is confirmed during intake.

If neither program settles it, the Gala Health review and the Fridays review cover two other programs we partner with, and each sets out its price and billing terms so you can run the same comparison.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxPallas Health
Value Score81 (B)74 (C+)
Advertised priceFrom $79/mo (compounded semaglutide; confirm total at checkout)$199/mo (Pallas's own average for $597 billed every 12 weeks — its only cadence)
Save vs brand self-pay——
SemaglutideFrom $79/mo (compounded injection; confirm total at checkout)$199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks
TirzepatideFrom $129/mo (compounded injection; confirm total at checkout)$299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks
Both moleculesYesYes
PricingWatchWatch
CoverageU.S., state limits shown at intakeAll 50 states and Washington D.C. — asynchronous in 43; Arkansas, Mississippi, New Mexico, North Dakota, Rhode Island, South Dakota, West Virginia and D.C. require one video visit

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

Lowest Real Price
CoreAge Rx: 88. Pallas Health: 72.
No Teaser-Rate Bait
CoreAge Rx: 74. Pallas Health: 55.
Nationwide Availability
CoreAge Rx: 45. Pallas Health: 96.
Both Molecules
CoreAge Rx: 95. Pallas Health: 88.
Easy Cancellation
CoreAge Rx: 88. Pallas Health: 70.
Reputation
CoreAge Rx: 84. Pallas Health: 78.

CoreAge Rx

CoreAge Rx advertises compounded semaglutide from $79 and tirzepatide from $129 per month, with dose-flat pricing stated in its FAQ. Confirm the total and refund terms before paying.

What's good

  • CoreAge Rx publishes separate product prices for both molecules: semaglutide from $79 per month and tirzepatide from $129. That gives you two actual medication offers to compare rather than one generic GLP-1 starting figure.
  • CoreAge Rx's FAQ says the price locked in at checkout stays the same in future months regardless of dose increases. I would save that confirmation with the order, because a low starting price matters much more when the prescribed maintenance dose costs the same.
  • The product pages state that there are no long-term contracts or membership fees and advertise fast, free delivery. Compare those inclusions with the checkout total; the refund policy separately allows applicable consultation fees and shipping charges if disclosed there.
  • CoreAge Rx uses the MD Integrations professional entities for medical care and prescribing. Its FAQ names physicians assigned in California, Massachusetts, Rhode Island and Vermont, giving patients in those states a concrete medical contact to verify.
  • CoreAge Rx offers account-based reordering and cancellation, and its help center says optional subscriptions can be managed in the member portal. Check whether your selected purchase is a one-time order or an automatically renewed subscription so the next charge is predictable.
  • CoreAge Rx also advertises microdosing products at $79 for semaglutide and $129 for tirzepatide. These are separate lower-dose offers, not a reason to select your own dose or evidence that they work like the doses studied for approved products.

The fine print

  • CoreAge Rx's FAQ promises an automatic 100% refund if the clinician declines your prescription, but its refund policy says applicable consultation fees of $50–$100 are nonrefundable. Ask which policy applies to the exact order and how much would be returned before you pay.
  • CoreAge Rx's refund policy makes a medication order final once the prescription is approved and sent to the pharmacy, which can happen before shipping. Waiting until the parcel is dispatched may be too late to cancel an order or recover the medication charge. The policy also imposes a 30-day nonrefundable cutoff even when incomplete documentation has prevented fulfillment.
  • CoreAge Rx does not publish a complete GLP-1 state list. Its FAQ says therapy-specific state restrictions are confirmed during intake, so a U.S. address alone does not establish that your selected medication is available where you live.
  • CoreAge Rx does not name the dispensing pharmacy in its FAQ; it asks patients to contact support. Obtain the pharmacy's legal name, license and contact information before choosing a compounded prescription. The platform's branding does not identify who prepares your medication.
  • CoreAge Rx's FAQ says there are no automatic rebills, while its refund policy and help center describe optional automatic renewals. I would confirm the selected purchase option and next charge date rather than treat the general FAQ answer as a guarantee for every order.
  • CoreAge Rx offers compounded medication, which is not FDA-approved. Its FAQ says tirzepatide is typically formulated with B12 and that requests without it go to the prescriber. Ask why the exact formulation is appropriate for you; an added vitamin does not itself establish a lawful patient-specific difference.

Pallas Health

Names its six dispensing pharmacies and two prescribing physicians' NPI numbers — disclosure few rows here offer — and then sells the whole thing on a single 12-week prepay whose advertised "$199/mo average" is that prepay divided by three, with no monthly rung to pick instead.

What's good

  • Names all six dispensing pharmacies in public — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — with the 503A and 503B distinction explained, where most GLP-1 sellers name none
  • Names two prescribing physicians with their NPI numbers and links to the federal NPPES registry so you can check them yourself: Dr. Ana Lisa Carr, MD (family medicine, NPI-verified, licensed in 15 states) and Dr. Kelly Tenbrink, MD (emergency medicine, NPI-verified, Tennessee and Florida). Pallas additionally claims obesity and addiction medicine board certifications for Dr. Carr, which the registry does not carry either way
  • The advertised price is the checkout price. The homepage FAQ, the landing pages, the treatment pages and the live funnel all state the same four figures, and no different number appears at the medication-select screen — the badge-versus-checkout gap this site keeps finding elsewhere is absent here
  • Both compounded molecules plus a real brand-name route on the same desk: Zepbound at $1,069/mo, Ozempic $1,299, Wegovy $1,349 and Mounjaro $1,349, cash-pay and billed monthly rather than quarterly
  • Publishes its coverage precisely instead of as a blanket promise — all 50 states and D.C., fully asynchronous in 43, with the eight jurisdictions needing a video visit named one by one, and a shipping-state check built into the checkout
  • Leaving is self-serve and free: a cancellation portal, a pre-renewal email reminder, no minimum term, at least 30 days' notice before any price change, and a full refund if a clinician declines you. Clean against FDA's live warning-letter database under its own name, its domain and its operator Brentmoor, Inc.

The fine print

  • There is no month-to-month rung and no term selector at all. Semaglutide is $139 for the first four weeks and then $597 billed every 12 weeks — the second charge is the full $597, in one payment, four weeks after the first — and tirzepatide is $179 then $897. The advertised "$199/mo average" is that 12-week prepay divided by three, not a price anyone is billed
  • Twelve weeks is not three months. On Pallas's own published renewal terms the charge recurs every 84 days, which is 4.35 times a year rather than four, so semaglutide's first year is $2,527 ($210.58/mo) and the steady state is about $2,596 a year (~$216/mo) against $199 advertised; tirzepatide runs $3,767 then about $3,900 (~$325/mo) against $299. The advertised average understates the ongoing rate by roughly 8.7%
  • The $139 and $179 headline numbers are intro rates, and the sitewide "Up to $120 off your first month" banner is a discount rather than a price
  • One of the six named pharmacies, Belmar, received an FDA warning letter issued 31 March 2023 (posted 18 April 2023), addressed to "Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy", over compounding practices — and FDA closed that letter out on 30 October 2023. Pallas itself carries no FDA warning letter under its own name, its domain or its operating company
  • Only two clinicians are named across the whole site, and the footer's "Provider directory" link resolves to a section naming the same two. The actual prescribing network — Lion MD's affiliated professional corporations — is not published
  • Money terms worth reading before you pay: $5 is deducted from each refunded payment for purchases made on or after 14 July 2026 (never on clinician-declined or unfulfilled orders, which refund in full), and the $60 visit deposit can be retained if you neither attend nor reschedule the required video visit in the eight jurisdictions that need one
  • Compounded semaglutide and tirzepatide are not FDA-approved and are not generic equivalents, which Pallas does disclose properly. Cash-pay only, with no insurance accepted ever, so the brand-name route at $1,069–$1,349/mo is far above what an insured patient pays
  • Several things a buyer would want are simply not published: whether baseline or follow-up lab work is included or charged extra, and whether the price rises with dose (there is no pre-purchase dose selector). The footer states that some site content is AI-generated with no warranty of accuracy, the advertised "4.8" rating carries no published source, and the before-and-after "Verified Customer" stories carry Pallas's own caveat that the individuals shown may be actors or models
Get the CoreAge Rx deal Get the Pallas Health deal

We earn a commission when you start treatment through some links on this site, at no extra cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Pallas Health.

More head-to-heads

The programs scoring closest to this pair, side by side.

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. "% vs brand-name self-pay" compares a program's lowest disclosed monthly price against $349/mo, Wegovy's self-pay price at NovoCare Pharmacy, every standard dose after the two-month intro offer (checked October 2026). Prices change — confirm on each provider's site. Not medical advice; see our disclosure.